RxDoctor Payments Data

Kristen Wernert, APRN

Gerontology · Louisville, KYNPI 1508386061

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.

$2,574in general payments, 2019–2025

Across 127 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$414
  • E.r. Squibb & Sons, L.L.C.$263
  • AstraZeneca$237
  • Novartis$225
  • Alnylam Pharmaceuticals Inc.$214
  • Pfizer$211
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$2,574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,574 in reported general payments places this provider in the 80th percentile of 84 gerontology providers in Kentucky.

See all gerontology providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,503
Medicare patients
42
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$41,406
EntrestoSacubitril/Valsartan32$39,572
FarxigaDapagliflozin Propanediol24$16,480
JardianceEmpagliflozin11$11,788
Bumetanide52$2,199
Potassium Chloride35$951
Amiodarone Hcl27$469
Spironolactone58$327
Torsemide13$319
Metoprolol Succinate24$294
Carvedilol17$282
Hydroxyzine Hcl16$199
Atorvastatin Calcium19$137
ClopidogrelClopidogrel Bisulfate16$68
Allopurinol13$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$211$41,40645 claims
NovartisEntresto$225$39,57232 claims
AstraZenecaFarxiga$237$16,48024 claims
Boehringer IngelheimJardiance$162$11,78811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 84 gerontology providers in Kentucky.

Other gerontology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →